BioAdvance

BioAdvance Capital is an evergreen fund that invests in early-stage life-science companies located in the Mid-Atlantic region of the United States, taking a long-term view on its investments. The firm says it continues to grow and invest while keeping its focus on that region, and describes its role as helping launch successful companies from within its portfolio. Companies in its portfolio have worked across areas including radiopharmaceuticals, physician retention research, tissue engineering and wearable respiratory monitoring, among others named on its site such as Immunome, Relmada Therapeutics and Ossianix. Its site also references board appointments at portfolio companies, including new director appointments at ImmunoGenesis and a new chairman and independent director at Latus Bio. BioAdvance Capital is based in Conshohocken, Pennsylvania.